📚 Lecture Overview
This lecture covers chronic leukemias, specifically focusing on Chronic Myeloid Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL). It details their origins, genetic markers, clinical presentations, diagnostic workflows, and current treatment options including targeted therapies.
🎯 Key Concepts & Definitions
- Leukemia: A heterogeneous group of hematologic malignancies arising from dysfunctional proliferation of developing leukocytes in the bone marrow and peripheral blood.
- Myeloid Leukemia: Leukemia originating from myeloid stem cells that normally develop into white blood cells, red blood cells, or platelets.
- Lymphocytic Leukemia: Leukemia originating from cells that develop into lymphocytes.
- Philadelphia Chromosome: A genetic abnormality (translocation t(9;22)) resulting in the BCR-ABL1 fusion gene, characteristic of CML.
- Chronic Lymphocytic Leukemia (CLL): A low-grade Non-Hodgkin lymphoma characterized by the uncontrolled proliferation of a malignant clone of mature lymphocytes.
- Leukemoid Reaction: A benign reactive leukocytosis (usually 50-100 x 10^3/cmm) with toxic granules, lacking the Philadelphia chromosome.
📖 Main Content
1. Chronic Myeloid Leukemia (CML) Origin & Genetics
- Originates from pluripotent stem cells involving a characteristic chromosomal translocation.
- Cytogenetics: Results in the Philadelphia chromosome (Ph chromosome) via reciprocal translocation t(9;22)(q34;q11).
- Molecular Background: Creates the BCR-ABL1 fusion gene, which encodes a constitutively active tyrosine kinase driving uncontrolled cell proliferation.
- Diagnostic Techniques: Conventional cytogenetics (karyotyping), FISH (Fluorescence In Situ Hybridization), and RT-PCR (Real-Time Polymerase Chain Reaction).
2. CML Clinical Picture & Laboratory Findings
- Phases: Progresses through three distinct phases: Chronic phase, Accelerated phase, and Blastic phase (blast crisis when blasts exceed 20%).
- Symptoms: Insidious onset, 30-50% asymptomatic, constitutional symptoms (weight loss, fatigue, night sweats), and massive splenomegaly (>75% of cases causing left upper quadrant pain).
- Lab Findings:
- Marked leukocytosis (WBC often >100 x 10^3/cmm, mainly neutrophilia).
- Basophilia is very common and diagnostic; eosinophilia and monocytosis also occur.
- Peripheral blood shows a "left shift" with metamyelocytes, myelocytes, and juvenile neutrophils.
- LAP score (Leukocyte Alkaline Phosphatase) is typically decreased (helps differentiate from leukomoid reactions).
- Increased uric acid, LDH, and potassium levels.
3. CML Treatment Options
- Tyrosine Kinase Inhibitors (TKIs): The cornerstone of CML treatment.
- First-generation: Imatinib.
- Second-generation: Dasatinib, Nilotinib.
- Third-generation: Ponatinib.
- Allogeneic stem cell transplantation used in advanced or resistant cases.
4. Chronic Lymphocytic Leukemia (CLL) Pathogenesis & Clinical Features
- Characteristics: Accumulation of monoclonal, functionally incompetent, long-lived mature B-lymphocytes (CD5+, CD19+, CD20+ low, CD23+).
- Clinical Presentation:
- ~25% asymptomatic, found incidentally on routine CBC showing absolute lymphocytosis.
- B symptoms (fever, drenching night sweats, weight loss) and symmetrical, painless lymphadenopathy.
- Autoimmune complications: Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
- Recurrent infections due to hypogammaglobulinemia.
5. CLL Diagnosis & Management
- Investigations: Peripheral blood flow cytometry (immunophenotyping showing characteristic score of 4-5/5).
- Staging & Prognosis: Assessed using Rai or Binet staging systems; prognostic markers include IgVH mutation status, del(17p), and TP53 mutations.
- Treatment Strategies:
- Watchful Waiting: For early-stage, asymptomatic patients.
- Targeted Therapy: Ibrutinib (BTK inhibitor) and Venetoclax (BCL-2 inhibitor).
- Immunotherapy: Monoclonal antibodies like rituximab and obinutuzumab.
- Chemotherapy, CAR T-cell therapy, and stem cell transplantation.
📊 Visual Learning
flowchart TD
A[Stem Cell Error] --> B{Cell Type}
B -->|Myeloid Cells| C[Chronic Myeloid Leukemia CML]
B -->|Lymphoid Cells| D[Chronic Lymphocytic Leukemia CLL]
C --> E[Philadelphia Chromosome BCR ABL1]
D --> F[Mature B Lymphocytes CD5 plus]
mindmap
root("CML Lab Findings")
"WBC Changes"
"Marked Leukocytosis"
"Neutrophilia"
"Diagnostic Basophilia"
"Enzymes and Scores"
"Decreased LAP Score"
"Increased LDH"
"Peripheral Smear"
"Left Shift"
"Myelocytes"
"Blasts under 10 percent in chronic phase"
sequenceDiagram
participant P as Patient
participant D as Doctor
participant Lab as Laboratory
P ->> D: Routine check up or fatigue
D ->> Lab: Order CBC and Peripheral Smear
Lab ->> D: Report Leukocytosis or Lymphocytosis
D ->> Lab: Order Cytogenetics or Flow Cytometry
Lab ->> D: Confirm BCR ABL1 or CLL Phenotype
💡 Important Points to Remember
- Hallmark of CML: Philadelphia chromosome t(9;22) producing the BCR-ABL1 fusion gene with tyrosine kinase activity.
- Diagnostic Basophilia: Basophilia is a hallmark feature of CML in the peripheral blood.
- LAP Score Difference: LAP score is decreased in CML, whereas it is increased in leukomoid reactions and infections.
- CLL Cell Type: CLL involves mature B-lymphocytes expressing CD5, CD19, and CD23.
- Autoimmune Manifestations: CLL frequently presents with Autoimmune Hemolytic Anemia (AIHA). AIHA alone without other symptoms does not require treatment.
- Blastic Phase Definition: CML enters the blastic phase (blast crisis) when blasts exceed 20% in blood or bone marrow.
- Targeted Drugs: Remember Ibrutinib (BTK inhibitor for CLL), Venetoclax (BCL-2 inhibitor for CLL), and Ponatinib (3rd gen TKI for CML).
- Watchful Waiting: Asymptomatic early-stage CLL patients are managed with observation ("watchful waiting").
- Mnemonic for CML TKIs: I Do Not Panic (Imatinib, Dasatinib, Nilotinib, Ponatinib).
⚠️ Common Exam Questions
- Examiner Trap 1: Confusing the LAP score in CML versus leukomoid reactions. Remember: CML has a low LAP score, while leukomoid reactions have a high LAP score.
- Examiner Trap 2: Assuming all lymphocytosis is malignant. Examiners test whether students can distinguish reactive lymphocytosis (infections) from clonal CLL using flow cytometry.
- Examiner Trap 3: Mixing up genetic translocations. Always link CML to t(9;22) and the Philadelphia chromosome.
- Short-Answer Trick: Asking for the blast percentage threshold that defines the blastic phase of CML (Answer: $≥$ 20%).
📝 Quick Review Checklist
I can explain the origin of CML and the role of the Philadelphia chromosome
I understand the distinct phases of CML and diagnostic lab findings like decreased LAP score
I can define CLL and its characteristic mature lymphocyte markers
I know how to differentiate CML from a leukomoid reaction
I understand the major treatment classes for both CML (TKIs) and CLL (targeted therapies, immunotherapy)